Subscribe

EKF Diagnostics Holdings plc (EKF.L)

GBp25.75 +0.15 (+0.59%)
GB LSE Healthcare Medical - Devices
Address Avon House CF64 2EZ
Cardiff, GB
CEO Gavin Joseph Jones
Website ekfdiagnostics.com
IPO 2000-01-04
ISIN GB0031509804

Explore sections of this company profile

Also trades on London Stock Exchange · EKF.L (GBp) Other OTC · EKDHF (USD)
Description

EKF Diagnostics Holdings plc, a company founded in 1990 and based in Cardiff, United Kingdom, operates as an international supplier of diagnostic solutions. The firm excels in the development, manufacturing, and distribution of a wide array of diagnostic instruments, chemical reagents, and associated products. Its extensive market reach spans across Europe, the Middle East, the Americas, Asia, Africa, and beyond. The company's product lineup addresses various critical diagnostic needs. This includes a range of hemoglobin analysis devices, such as the handheld DiaSpect Tm and the quantitative Hemo Control. EKF also provides advanced glucose and lactate analyzers like the Biosen C-Line series, alongside point-of-care solutions for diabetes management, exemplified by the Quo-Lab A1c and Quo-Test A1c. Beyond these, their offerings extend to specialized diagnostic tools: the Creamatocrit Plus for assessing lipid concentration in mothers' milk, QuPID and True20 pregnancy tests, and the STAT-Site M Beta-hydroxybutyrate analyzer. EKF further supplies a comprehensive suite of clinical chemical analyzers and reagents, designed for monitoring conditions such as ketosis, glycated albumin, glycated serum protein, and utilizing markers like Procalcitonin for bacterial infections and sepsis. Additional provisions include immunoassay kits, general chemistry analyzers like the Altair 240, micro centrifuges, the Uri-Trak 120 urine analyzer, and dedicated kits and services for COVID-19. The company also offers its manufacturing capabilities as contract solutions to third-party businesses and delivers professional laboratory services.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
GBp25.75 +0.15 (+0.59%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
304.1K
Beta
0.51
Float Shares
351.18M
Free Float %
81.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-1.65% -2.37% +0.19% +3.68% +11.46% +1.33% +7.00% -5.31% -65.26% +132.61% -92.48%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
25.75
DCF (Unlevered) 21.91 -14.9%
DCF (Levered) 55.79 +116.7%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 3 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
9.49
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Devices: +11.2%
    +2.7% Q4'25: +2.3% (vs Q4'23)
  • ✗
    EPS growth Medical - Devices: +28.5%
    -65.9% Q4'25: -93.3% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Medical - Devices: +30.9%
    +3.0% Q4'25: +14.2% (vs Q4'23)
  • ✗
    EBIT margin Medical - Devices: +6.2%
    +13.1% ★ Q4'25: +12.4% (vs Q4'23)
  • ✗
    ROIC Medical - Devices: +3.3%
    +7.3% ★ Q4'25: +14.0% (vs Q4'23)
  • ✓
    Share dilution Medical - Devices: 0.0%
    -1.2% ★ Q4'25: -1.2% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×
    0.21× ★ Q4'25: 0.05× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.53) × ERP
WACC = 99% × Ke + 1% × Kd (11.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 21.91 Current price: 25.75
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2006
actual 		Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
3 Rev. Ana.
2 EPS Ana. 		Dec 2027
3 Rev. Ana.
3 EPS Ana. 		Dec 2028
3 Rev. Ana.
1 EPS Ana. 		Dec 2029
2 Rev. Ana.
1 EPS Ana.
Revenue
3.08M
est: 3.45M (-10.8%)
21.66M
est: 20.09M (+7.8%)
26.06M
est: 27.13M (-3.9%)
31.80M
est: 32.45M (-2.0%)
40.06M
est: 40.10M (-0.1%)
30.05M
est: 45.90M (-34.5%)
38.59M
est: 38.10M (+1.3%)
41.58M
est: 41.36M (+0.5%)
42.54M
est: 42.99M (-1.0%)
44.92M
est: 45.62M (-1.5%)
65.26M
est: 64.65M (+0.9%)
81.84M
est: 73.79M (+10.9%)
66.64M
est: 65.95M (+1.0%)
52.61M
est: 50.95M (+3.3%)
50.19M
est: 50.22M (0.0%)
51.56M
est: 51.60M (-0.1%)
54.62M
54.50M – 54.77M
+5.9% YoY
58.38M
58.10M – 58.93M
+6.9% YoY
61.84M
61.84M – 61.85M
+5.9% YoY
65.37M
65.14M – 65.78M
+5.7% YoY
EBITDA
591.0K
est: 674.5K (-12.4%)
187.0K
est: 3.49M (-94.6%)
3.03M
est: -904.8K (+434.5%)
4.52M
est: 5.24M (-13.8%)
1.75M
est: 3.74M (-53.2%)
-7.35M
est: 1.10M (-769.4%)
4.46M
est: -26.31M (+117.0%)
8.43M
est: 3.55M (+137.6%)
16.19M
est: 8.60M (+88.4%)
10.02M
est: 16.91M (-40.8%)
20.04M
est: 12.43M (+61.3%)
27.39M
est: 10.25M (+167.1%)
-2.18M
est: 9.75M (-122.4%)
7.68M
est: 8.16M (-5.9%)
11.16M
est: 7.71M (+44.8%)
6.75M
est: 8.27M (-18.4%)
8.75M
8.73M – 8.77M
+5.9% YoY
9.35M
9.31M – 9.44M
+6.9% YoY
9.91M
9.91M – 9.91M
+5.9% YoY
10.47M
10.44M – 10.54M
+5.7% YoY
EBIT
586.0K
est: 370.4K (+58.2%)
-2.13M
est: 3.43M (-162.1%)
-52.0K
est: -2.75M (+98.1%)
971.0K
est: 846.3K (+14.7%)
-3.20M
est: 2.97M (-207.8%)
-15.40M
est: -2.22M (-595.0%)
-498.0K
est: -12.11M (+95.9%)
4.41M
est: -356.6K (+1,337.5%)
12.20M
est: 4.89M (+149.3%)
5.58M
est: 12.94M (-56.9%)
15.43M
est: 7.62M (+102.6%)
21.50M
est: 6.28M (+242.3%)
-8.84M
est: 5.98M (-247.9%)
2.21M
est: 4.39M (-49.8%)
6.43M
est: 4.33M (+48.6%)
6.75M
est: 4.45M (+51.7%)
4.71M
4.70M – 4.72M
+5.9% YoY
5.03M
5.01M – 5.08M
+6.9% YoY
5.33M
5.33M – 5.33M
+5.9% YoY
5.64M
5.62M – 5.67M
+5.7% YoY
Net Income
596.0K
est: 6.40M (-90.7%)
-2.88M
est: 3.49M (-182.6%)
1.83M
est: -3.89M (+147.1%)
-1.13M
est: 2.78M (-140.5%)
-5.69M
est: -1.40M (-307.4%)
-37.12M
est: -6.50M (-471.3%)
-18.0K
est: -31.34M (+99.9%)
2.72M
est: -19.6K (+13,931.6%)
10.11M
est: 2.81M (+259.8%)
3.68M
est: 10.72M (-65.7%)
11.11M
est: 4.84M (+129.5%)
15.85M
est: 3.99M (+296.8%)
-10.10M
est: -12.67M (+20.3%)
2.35M
6.24M
est: 4.96M (+25.9%)
2.12M
est: 6.45M (-67.1%)
7.54M
6.69M – 7.79M
+16.8% YoY
8.30M
7.47M – 8.83M
+10.1% YoY
9.22M
9.18M – 9.29M
+11.1% YoY
10.76M
10.71M – 10.84M
+16.7% YoY
SGA
894.0K
est: 1.03M (-13.2%)
9.30M
est: 6.46M (+43.9%)
14.65M
est: 14.30M (+2.4%)
14.44M
est: 17.46M (-17.3%)
22.79M
est: 20.12M (+13.3%)
29.16M
est: 20.89M (+39.6%)
18.73M
est: 17.94M (+4.4%)
18.19M
est: 15.32M (+18.7%)
10.59M
est: 17.09M (-38.1%)
18.28M
est: 14.72M (+24.2%)
20.66M
est: 19.71M (+4.8%)
17.71M
est: 16.26M (+8.9%)
23.18M
est: 15.47M (+49.8%)
17.88M
est: 15.24M (+17.3%)
13.68M
est: 15.02M (-8.9%)
16.43M
est: 15.43M (+6.5%)
16.33M
16.30M – 16.38M
+5.9% YoY
17.46M
17.37M – 17.62M
+6.9% YoY
18.49M
18.49M – 18.50M
+5.9% YoY
19.55M
19.48M – 19.67M
+5.7% YoY
EPS
0.02
est: 0.01 (+27.6%)
-0.01
est: -0.25 (+94.5%)
0.01
est: 0.00 (+838.6%)
0.00
est: 0.00 (-358.2%)
-0.02
est: 0.00 (-528.3%)
-0.09
est: 0.01 (-1,306.6%)
0.00
est: 0.00 (-101.0%)
0.01
est: 0.01 (-16.0%)
0.02
est: 0.01 (+89.1%)
0.01
est: 0.01 (-43.9%)
0.02
est: 0.04 (-34.1%)
0.03
est: 0.04 (-7.6%)
-0.02
est: 0.02 (-219.8%)
0.01
0.01
est: 0.01 (+24.3%)
0.00
est: 0.01 (-67.8%)
0.02
0.01 – 0.02
+12.7% YoY
0.02
0.02 – 0.02
+12.5% YoY
0.02
0.02 – 0.02
+11.1% YoY
0.02
0.02 – 0.02
+16.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A- 4/5 5/5 3/5 4/5 4/5 1/5 3/5
2026-05-28 A- 4/5 5/5 3/5 4/5 4/5 1/5 3/5
2026-05-27 A- 4/5 5/5 3/5 4/5 4/5 1/5 3/5
2026-05-26 A- 4/5 5/5 3/5 4/5 4/5 1/5 3/5
2026-05-22 B+ 3/5 5/5 3/5 4/5 3/5 1/5 3/5
2026-05-21 B+ 3/5 5/5 3/5 4/5 3/5 1/5 3/5
2026-05-20 B+ 3/5 5/5 3/5 4/5 3/5 1/5 3/5
2026-05-19 B+ 3/5 5/5 3/5 4/5 3/5 1/5 3/5
2026-05-18 B+ 3/5 5/5 3/5 4/5 3/5 1/5 3/5
2026-05-15 B+ 3/5 5/5 3/5 4/5 3/5 1/5 3/5
2026-05-14 B+ 3/5 5/5 3/5 4/5 3/5 1/5 3/5
2026-05-13 B+ 3/5 5/5 3/5 4/5 3/5 1/5 3/5
2026-05-12 B+ 3/5 5/5 3/5 4/5 3/5 1/5 3/5
2026-05-11 B+ 3/5 5/5 3/5 4/5 3/5 1/5 3/5
2026-05-08 B+ 3/5 5/5 2/5 4/5 3/5 1/5 4/5
2026-05-07 B+ 3/5 5/5 2/5 4/5 3/5 1/5 4/5
2026-05-06 B+ 3/5 5/5 2/5 4/5 3/5 1/5 4/5
2026-05-05 B+ 3/5 5/5 2/5 4/5 3/5 1/5 4/5
2026-05-01 B+ 3/5 5/5 2/5 4/5 3/5 1/5 4/5
2026-04-30 B+ 3/5 5/5 2/5 4/5 3/5 1/5 4/5
2026-04-29 B+ 3/5 5/5 2/5 4/5 3/5 1/5 3/5
2026-04-28 B+ 3/5 5/5 2/5 4/5 3/5 1/5 3/5
2026-04-27 B+ 3/5 5/5 2/5 4/5 3/5 1/5 3/5
2026-04-24 B 3/5 5/5 2/5 4/5 2/5 1/5 3/5
2026-04-23 B 3/5 5/5 2/5 4/5 2/5 1/5 3/5
2026-04-22 B 3/5 5/5 2/5 4/5 2/5 1/5 3/5
2026-04-21 B+ 3/5 5/5 2/5 5/5 2/5 1/5 3/5
2026-04-20 B+ 3/5 5/5 2/5 5/5 2/5 1/5 3/5
2026-04-17 B+ 3/5 5/5 2/5 5/5 2/5 1/5 3/5
2026-04-16 B+ 3/5 5/5 2/5 5/5 2/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
14.04M
OE per share TTM
0.03
Owner's Yield
11.71%
Maintenance CapEx ratio
476.91%
Maint CapEx / Avg PPE
33.3%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 1 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares International Small-Cap Equity Factor ETF ISCF 0.03% 179.2K 0.24%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
22.3K
Shares Outstanding
430.50M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Helen Mary Kinsey Jones Chief Financial Officer & Director 305.0K female
Julian Huw Baines Executive Chairman 261.0K male
Gavin Joseph Jones Chief Executive Officer & Director 234.6K male
Stephen Young Chief Financial Officer & Executive Director 225.0K male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Devices